IP Library Patent Application 19077379
Patent Application
App. No. 19/077,379

HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/077,379
Abstract

Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

Claims (24)

1 . A human antibody which binds human Tissue Factor, wherein the antibody comprises:

(a) a VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:14, 15 and 16 and a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 70, 71 and 72,

(b) a VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 18, 19, 20 and a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:74, 75 and 76,

(c) a VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:22, 23 and 24 and a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 78, 79 and 80,

(d) a VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 26, 27 and 28 and a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 82, 83 and 84, or

(e) a variant of any of (a)-(d), wherein said variant has at most 1, 2 or 3 amino-acid modifications.

2 - 66 . (canceled)

67 . A bispecific molecule comprising the antibody of claim 1 and a second binding specificity for a human effector cell, a human Fc receptor or a T cell receptor.

68 . An expression vector comprising a nucleotide sequence encoding one or more of the amino acid sequences of the antibody of claim 1 .

69 . (canceled)

70 . A recombinant eukaryotic or prokaryotic host cell which produces the antibody as defined in claim 1 .

71 . A pharmaceutical composition comprising the antibody as defined in claim 1 or a bispecific molecule comprising the antibody of claim 1 and a second binding specificity, and a pharmaceutically acceptable carrier.

72 - 83 . (canceled)

84 . A method for inhibiting growth and/or proliferation of a tumor cell expressing Tissue Factor, comprising administration, to an individual in need thereof, of an antibody of any of claim 1 or a bispecific molecule comprising the antibody of claim 1 and a second binding specificity.

85 . A method for producing the antibody of claim 1 , said method comprising the steps of

a) culturing a recombinant eukaryotic or prokaryotic host cell which produces the antibody as defined in claim 1 , and

b) purifying the antibody from the culture media.

86 . A diagnostic composition comprising the antibody as defined in claim 1 .

87 . A method for detecting the presence of Tissue Factor in a sample, comprising:

contacting the sample with an antibody of claim 1 , or a bispecific molecule comprising the antibody of claim 1 and a second binding specificity, under conditions that allow for formation of a complex between the antibody or bispecific molecules and Tissue Factor; and

analyzing whether a complex has been formed.

88 . A kit for detecting the presence of Tissue Factor in a sample comprising

an antibody of claim 1 or a bispecific molecule comprising the antibody of claim 1 and a second binding specificity; and

instructions for use of the kit.

Assignments (2)
SECURITY INTEREST Recorded Dec 15, 2025
From: GENMAB A/S; GENMAB B.V.; GENMAB HOLDING B.V.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 073933/0597 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 15, 2025
From: GENMAB A/S; GENMAB B.V.; GENMAB HOLDING B.V.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 073949/0722 →